About
Dr. Carter earned a First-Class Honours degree in Biochemistry from the University of Southampton in 2008. He then pursued a PhD under the guidance of Professor Mark Cragg, focusing on the molecular regulation of apoptosis in B-cell malignancies. This research deepened his understanding of complex cell survival mechanisms, particularly the role of BH3-only members of the BCL-2 family.
Following his PhD, Dr. Carter continued his research as a postdoctoral fellow in the same lab, investigating the impact of isoform-selective PI3 kinase inhibitors on antibody therapeutics in B-cell cancers. These studies uncovered that the mechanism of action of PI3 kinase inhibitors was linked to increased cellular apoptosis, mediated by the BIM BH3-only protein. Accordingly, a novel combinational therapeutic strategy was devised, based on this new understanding, which reduced tumour burden by 96% in pre-clinical models. More recently, Dr. Carter has explored the mechanisms of action of innovative antibody immunotherapies and bromodomain inhibitors targeting the BET family.